Literature DB >> 28011489

Prognostic Impact of CD163+ Macrophages in Tumor Stroma and CD8+ T-Cells in Cancer Cell Nests in Invasive Extrahepatic Bile Duct Cancer.

Takuya Miura1, Tadashi Yoshizawa2, Hideaki Hirai2, Hiroko Seino2, Satoko Morohashi2, Yunyan Wu2, Taiichi Wakiya3, Norihisa Kimura3, Daisuke Kudo3, Keinosuke Ishido3, Yoshikazu Toyoki3, Hiroshi Kijima2, Kenichi Hakamada3.   

Abstract

AIM: The aim of this study was to examine the clinicopathological influence of tumor-infiltrating cluster of differentiation (CD) 163+ macrophages and CD8+ T-cells, and to clarify the prognostic effects of these cells in patients with invasive extrahepatic bile duct cancer (EHBC).
MATERIALS AND METHODS: The numbers of CD8+ T-cells in cancer cell nests and CD163+ macrophages in tumor stroma were evaluated using immunohistochemistry in 101 resected EHBC specimens. Correlations with clinicopathological variables and overall survival were analyzed.
RESULTS: Perihilar EHBC and perineural invasion were significantly associated with a low number of tumor-infiltrating CD8+ T-cells. Poorly- differentiated histology and nodal metastasis were significantly associated with a high number of tumor-infiltrating CD163+ macrophages. A combination of high number of CD8+ T-cells and low number of CD163+ macrophages was independently related to better overall survival in the whole patient cohort (hazard ratio=0.127, p<0.001) and in patients treated with adjuvant chemotherapy (hazard ratio=0.139, p=0.021).
CONCLUSION: Infiltrating CD163+ macrophages in tumor stroma and CD8+ T-cells in cancer cell nests have a prognostic impact in patients with EHBC following resection and also after adjuvant chemotherapy. Copyright
© 2017 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  CD163; CD8; Extrahepatic bile duct cancer; tumor-associated macrophages; tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2017        PMID: 28011489     DOI: 10.21873/anticanres.11304

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  19 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

3.  Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.

Authors:  Taek Chung; Hyungjin Rhee; Hyo Sup Shim; Jeong Eun Yoo; Gi Hong Choi; Haeryoung Kim; Young Nyun Park
Journal:  Gut Liver       Date:  2021-11-23       Impact factor: 4.321

4.  CD40 Agonists Alter the Pancreatic Cancer Microenvironment by Shifting the Macrophage Phenotype toward M1 and Suppress Human Pancreatic Cancer in Organotypic Slice Cultures.

Authors:  Chae Yoon Lim; Jae Hyuck Chang; Won Sun Lee; Jeana Kim; Il Young Park
Journal:  Gut Liver       Date:  2021-12-21       Impact factor: 4.321

Review 5.  The Tumor Microenvironment in Cholangiocarcinoma Progression.

Authors:  Luca Fabris; Keisaku Sato; Gianfranco Alpini; Mario Strazzabosco
Journal:  Hepatology       Date:  2020-11-06       Impact factor: 17.298

6.  Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients.

Authors:  Xiaobo Bo; Jie Wang; Tao Suo; Xiaoling Ni; Han Liu; Sheng Shen; Min Li; Yueqi Wang; Houbao Liu; Jiejie Xu
Journal:  BMC Cancer       Date:  2018-03-21       Impact factor: 4.430

7.  Fucosyl-Agalactosyl IgG₁ Induces Cholangiocarcinoma Metastasis and Early Recurrence by Activating Tumor-Associated Macrophage.

Authors:  Ting-Tsung Chang; Hung-Wen Tsai; Cheng-Hsun Ho
Journal:  Cancers (Basel)       Date:  2018-11-21       Impact factor: 6.639

Review 8.  Diverse Functions of Macrophages in Different Tumor Microenvironments.

Authors:  Ming Yang; Daniel McKay; Jeffrey W Pollard; Claire E Lewis
Journal:  Cancer Res       Date:  2018-09-11       Impact factor: 12.701

9.  Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection.

Authors:  Hu Liu; Guoteng Qiu; Fengjuan Hu; Hong Wu
Journal:  World J Surg Oncol       Date:  2021-07-20       Impact factor: 2.754

10.  Distribution pattern of tumor associated macrophages predicts the prognosis of gastric cancer.

Authors:  Jiu-Yang Liu; Chun-Wei Peng; Gui-Fang Yang; Wen-Qing Hu; Xiao-Jun Yang; Chao-Qun Huang; Bin Xiong; Yan Li
Journal:  Oncotarget       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.